Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wiewrodt

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
The Clinical Respiratory Journal|April 12, 2017
Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lungA B Schulze, L H Schmidt, L Baie, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLCL H Schmidt, A Kuemmel, C Schliemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
The Clinical Respiratory Journal|April 12, 2017
Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lungA B Schulze, L H Schmidt, L Baie, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLCL H Schmidt, A Kuemmel, C Schliemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
Pageof 4